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Dear Editor
In their publication of the National Institute for Health and
Clinical Excellence (NICE) single technology appraisal of
eltrombopag, Boyers et al. [1] report the results of the
indirect treatment comparison (ITC) of eltrombopag and
romiplostim, conducted by GlaxoSmithKline (GSK) [the
manufacturer of eltrombopag] and made available to NICE
as part of the single technology appraisal of eltrombopag.
Subsequent to the appraisal process, GSK identified and
corrected a methodological error in this analysis (available
at http://www.gsk-clinicalstudyregister.com [study ID:
114014]). NICE were made aware of this error in
November 2010. This correction was not published as part
of the original assessment of eltrombopag and is not used
in the Boyers et al. publication [1]. GSK would like to alert
the readers of PharmacoEconomics to the corrected data
and interpretation of this analysis. The nature of the error,
the corrected results and the impact on the conclusions of
the article are outlined below.
1 Indirect Comparison Methodology
The analysis is the indirect comparison of durable and
overall platelet response between eltrombopag and romi-
plostim based on two trials with romiplostim and one with
eltrombopag (RAISE; Randomized Placebo-Controlled
Idiopathic Thrombocytopenic Purpura Study with
Eltrombopag). The primary endpoint in the romiplostim
studies (the probability of achieving a durable response) [2]
differs from the primary endpoint in RAISE: the odds of
achieving a platelet count C50\400 9 109/L [3]. An indi-
rect comparison of durable and overall response was per-
formed on a post hoc analysis of RAISE and the romiplostim
studies applying the Bucher method [4]. Although the el-
trombopag and romiplostim studies were conducted in
similar patient populations, there are important differences
in study design and in the definitions of response that intro-
duce uncertainty and bias into the comparison. This should
be taken into account in any interpretation of the analysis.
The analyses originally provided to NICE and subsequently
presented by Boyers et al. [1] used incorrect efficacy data
extracted from a subset of patients in RAISE, which should
have been taken from the intent-to-treat (ITT) population.
2 Corrected Results
The durable and overall response rates were recalculated
using data from the ITT population.
The results of the indirect comparisons of platelet
response (eltrombopag compared with romiplostim),
updated using the ITT data, are presented in Tables 1 and 2.
No evidence of a significant difference in the odds of
achieving either a durable or an overall response was
identified between the eltrombopag and romiplostim treat-
ment groups in analyses of all patients, splenectomized
patients and non-splenectomized patients.
3 Interpretation
There is inherent uncertainty in any indirect comparison
and such analyses should be treated with caution. There are
R. Allen (&)  A. Brainsky  K. Grotzinger  T. Roccia
GlaxoSmithKline Ltd, 1–3 Iron Bridge Road,




several additional factors that increase the uncertainty of
the analysis in this particular case:
• The main outcome of the comparison, durable
response, was the primary endpoint of the romiplostim
studies and a post hoc analysis for eltrombopag; this
means that whilst the romiplostim studies were specif-
ically planned to address the aforementioned outcome,
RAISE was not.
• One of the outcomes presented by Boyers et al. [1] is
overall response, which is the sum of ‘durable
response’ and ‘transient response’. Durable response
was similarly defined in the romiplostim trials and the
eltrombopag post hoc analysis: a response in at least six
of the last eight visits of the treatment period. However,
the definition of ‘transient response’ was different: a
transient response in the romiplostim analysis required
a response at any four, weekly visits during the study,
whereas the eltrombopag analysis required four con-
secutive weekly visits. In a disease where platelet
counts fluctuate, four consecutive responses are more
difficult to achieve and this is likely to have biased the
ITC against eltrombopag.
• Whilst the romiplostim study did not allow tapering or
interruptions of concomitant immune thrombocytope-
nic purpura (ITP) medications during the last 12 weeks
of study, in RAISE physicians were encouraged to
reduce concomitant ITP medications once a stable dose
of eltrombopag was achieved. This was more likely to
occur towards the end of the trial, when durable
response was assessed in the post hoc analysis. Platelet
count fluctuations are expected as a result of tapering
ITP medications, and this most likely negatively
impacted the response estimates for eltrombopag.
• The number of durable and overall responders in the
placebo arm of the romiplostim study was very low. As
such, any indirect comparison will be very sensitive to
small changes in this event rate.
4 Conclusion
The corrected ITC demonstrates that there is no evidence
of a statistically significant difference in durable or overall
response between eltrombopag and romiplostim for all
patients, splenectomized patients or non-splenectomized
patients. Results should be interpreted in the context of the
significant uncertainty associated with this comparison, in
an orphan disease area, where there is a paucity of robust
evidence.
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Table 1 Comparison of efficacy between eltrombopag and romiplostim: durable response
Treatment OR vs. placebo
(95% CI)
Treatment OR vs. placebo
(95% CI)
Indirect comparison eltrombopag vs.
romiplostim [OR (95% CI)]
All subjects
Eltrombopag 12.69 (4.36, 36.92) Romiplostim 40.02 (5.26, 304.70) 0.32 (0.03, 3.14)
Splenectomized subjects
Eltrombopag 13.33 (1.66, 107.43) Romiplostim 26.77 (1.52, 472.41) 0.50 (0.01, 17.32)
Non-splenectomized subjects
Eltrombopag 12.97 (3.72, 45.26) Romiplostim 31.25 (3.81, 256.24) 0.41 (0.04, 4.80)
OR odds ratio
Table 2 Comparison of efficacy between eltrombopag and romiplostim: overall response
Treatment OR vs. placebo
(95% CI)
Treatment OR vs. placebo
(95% CI)
Indirect comparison eltrombopag vs.
romiplostim [OR (95% CI)]
All subjects
Eltrombopag 13.96 (6.12, 31.86) Romiplostim 64.07 (17.33, 236.82) 0.22 (0.05, 1.02)
Splenectomized subjects
Eltrombopag 14.25 (2.98, 68.02) Romiplostim 151.63 (8.39, 2741.84) 0.09 (0.00, 2.52)
Non-splenectomized subjects
Eltrombopag 14.83 (5.53, 39.76) Romiplostim 43.20 (9.27, 201.33) 0.34 (0.06, 2.14)
OR odds ratio
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